(Q36912988)

17 August 2017

title

Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones (English)

1 reference

17 August 2017

0 references

Jörg B Engel

1

0 references

Andrew Schally

object named as

Andrew V Schally

series ordinal

2

0 references

Arnd Hönig

series ordinal

5

object named as

Arnd Hönig

1 reference

17 August 2017

Johannes Dietl

3

1 reference

17 August 2017

Lorenz Rieger

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

18 August 2007

1 reference

17 August 2017

published in

Molecular Pharmaceutics

1 reference

17 August 2017

volume

4

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

652-658

1 reference

High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin

17 August 2017

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Cancer statistics, 2003.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Cancer statistics, 2005

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Expression of gastrin-releasing peptide receptors in endometrial cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Hypothalamic hormones and cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Chemotherapy targeted to cancers through tumoral hormone receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1021/MP0700514

Identifiers

DOI

10.1021/MP0700514

1 reference

17 August 2017

1 reference